B&D Nutritional Ingredients, Inc., a raw material distributor in the dietary supplement industry and exclusive U.S. distribution partner to CarnoSyn ® Brands and Natural Alternatives International, ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in ...

GLP-1 receptor agonists, like Ozempic and Wegovy, have been everywhere over the past few years, and research seems to be ...

Eli Lilly & Co. Inc.'s stock (LLY) rose 1.5% early Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk's Wegovy in a head-to-head study.

Kara Kennedy's husband was a yo-yo dieter for decades, until he discovered Zepbound – an Ozempic-like drug – and lost 3.5 ...

Eli Lilly & Co. Inc.’s stock rose 1.5% early Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk’s Wegovy in a head-to-head study. Zepbound ...

Embecta Corp.'s Q4 results showed significant net income and EPS growth. Embecta also announced a restructuring plan. See why ...

Most people taking popular drugs like Ozempic and Wegovy to lose weight have shed significant pounds. But obesity experts say that roughly 20% of patients — as many as 1 in 5 — may not see robust ...

Antag Therapeutics thinks its glucose dependent insulinotropic polypeptide receptor (GIPR) antagonist could carve out a space ...

Last year’s study in the journal Obesity had revealed that of people prescribed weight-loss drugs, just 44 per cent were ...

The American Diabetes Association (ADA) urged healthcare providers against prescribing non-FDA approved compounded GLP-1 and ...

Research reports that in the United States, the number of patients who underwent bariatric procedure decreased by 25%, while ...